Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 10:30am CEST

Release date- 04102017 - Paris, France - Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effective immediately.

In this role, Mr. Oelrich will be a member of the Executive Committee.

'Stefan is a highly effective leader who has demonstrated his ability to deliver strong results during his tenure at Sanofi,' said Olivier Brandicourt, Sanofi's Chief Executive Officer. 'As one of the architects of our Diabetes & Cardiovascular business unit, I am confident Stefan will succeed in driving our strategy forward in the coming years.'

Mr. Oelrich has served as head of Sanofi's global diabetes franchise since June 2016 and as acting head of the DCV North America business since July. He will continue to lead both functions ad interim until successors are named.

He previously served as DCV Europe Region Head & Sanofi Europe Coordinator, and was heavily involved in establishing the DCV global business unit since mid-2015. Between 2011 and 2015 he served as General Manager in Germany, Switzerland and Austria.

Mr. Oelrich began his career in Bayer AG in Germany in 1992 where he held positions of increasing responsibility and leadership across Latin America, Europe and the US including General Manager for Bayer Healthcare in Belgium and in France. He led Bayer Pharmaceutical's US Marketing as VP of Marketing followed by a promotion to SVP & General Manager US Women's Healthcare.

A citizen of Germany, Mr. Oelrich holds a Master's degree in Business Administration from the Business School of the Cologne Chamber of Commerce.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Jack Cox

Tel: +33 (0)1 53 77 46 46

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
01:48aWISETECH GLOBAL (ASX : WTC) Acquires Three Leading Logistics Solution Providers ..
04/21SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
04/20SANOFI : Advent International enters into exclusive negotiations to acquire Zent..
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
More news
News from SeekingAlpha
12:13aMANNKIND : Experts In Pulling Numbers From Orifices 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 633 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,71%
P/E ratio 2018 16,06
P/E ratio 2019 14,21
EV / Sales 2018 2,76x
EV / Sales 2019 2,59x
Capitalization 82 385 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 21%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 746
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890